Macula Risk®

What is Macula Risk®?

Approximately 75% of AMD is caused by genetic variations that are inherited from one’s parents.

Macula Risk® stratifies patients into Risk Categories allowing patient specific monitoring and treatment programs.
MaculaRisk_graph

AMD is a disease that may be arrested but it is not reliably reversible.  Early detection and intervention is critical to the prevention of vision loss.  Individuals who are at risk (Macula Risk® Level 3, 4 and 5) can benefit from:

1.    Routine surveillance and measurement of the health of their eyes (e.g. PHP);
2.    Patient education and at-home testing (e.g.  Amsler grid);
3.    Preventative vitamin therapy (e.g, AREDS vitamins);
4.    Early diagnosis and treatment (e.g. Lucentis, Visudine);

Clinical Validation: Macula Risk®

A large independent prospective clinical trial including many (but not all) of the genes in Macula Risk® has now demonstrated an 83% predictive value when genetics are used in combination with other factors such as smoking history to predict vision loss in AMD. This study published in May 2009 in IOVS by Dr. J. Seddon of Tufts University included a smaller number of gene variants than Macula Risk®.
MaculaRisk_boxkit

More information on Macula Risk®.